A randomized phase III study optimizing adjuvant osimertinib for resected EGFR -mutant stage II–III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01)

Clicks: 13
ID: 337739
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #23 of 26 articles by views in japanese journal of clinical oncology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The OASIS trial [Japan Cancer Treatment Optimization group (JACTOP)-01] is a multicenter, randomized, open-label, phase III study optimizing adjuvant osimertinib therapy for patients with completely resected, epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) stage II–III non-squamous non-small cell lung cancer. Based on the ADAURA trial, the standard adjuvant dose of osimertinib is 80 mg/day, which often causes significant adverse events and financial toxicity. This trial evaluates the non-inferiority of a reduced dose of 40 mg/day of osimertinib compared to the standard 80 mg/day. A total of 420 patients will be randomized (1:1) to receive either osimertinib 80 or 40 mg/day orally for 3 years. The primary endpoint is disease-free survival. Secondary endpoints include overall survival, central nervous system disease-free survival, safety, and quality of life. If non-inferiority is confirmed, osimertinib 40 mg/day will establish a new optimal adjuvant strategy, improving patient quality of life and reducing medical economic burdens.
Reference Key
openalex_W7224615382 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ken Onodera, Yoshinori Okada, Yujin Kudo, Masaya Yotsukura, Keisuke Asakura, Yasushi Goto, Satoshi Shiono, Shinichi Toyooka, Yoshimasa Maniwa, Toyofumi Fengshi Chen-Yoshikawa, Shun-ichi I. Watanabe, Masataka Taguri, Nodoka Seya, Tomonori Mizutani, Hideo Kunitoh, the Japan Cancer Treatment Optimization group (Jactop), Norihiko Ikeda
Are you one of these authors? Claim your profile
Journal japanese journal of clinical oncology
Year 2026
DOI
10.1093/jjco/hyag185
URL
https://doi.org/10.1093/jjco/hyag185
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.